ArticleCureus2026
Glenoid Augmentation With Humeral Head Autograft in Reverse Shoulder Arthroplasty: A Retrospective Study of an Innovative Technique.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The use of reverse shoulder arthroplasty (RSA) is expanding for both primary and revision procedures. Advances in implant technology and preoperative planning have improved the ability to manage complex glenoid defects. Various options are available for addressing severe glenoid bone loss, including eccentric reaming, glenoid reconstruction with bone graft, and the use of augmented glenoid baseplates. However, metal augments are often expensive and lead to more waste and CO₂ emissions, adding to our carbon footprint. Humeral head autografts are an excellent alternative, as they preserve bone and incorporate very well. We conducted a retrospective study and described a new innovative technique when using humeral head autograft for glenoid bone loss in reverse shoulder arthroplasty. Methods A retrospective review of 24 patients who underwent glenoid augmentation using humeral head autografts for reverse shoulder arthroplasty from 2017 to 2024. The majority of the patients were female, with a mean age of 75.4 years. All patients had a preoperative CT scan to assess glenoid bone loss and were classified as per Walch's classification. All patients were operated on by two consultant shoulder surgeons. A femoral head allograft was available for all as a standby in case of poor bone quality in the humeral head; however, this was only used in one patient. The deltoid-splitting McKenzie approach and a Delta Xtend reverse shoulder system (DePuy) were used in all patients. The humeral head was prepared to match the glenoid defect. The graft was held in place with a K-wire, followed by Metagelene; a log peg was used in most cases. Clinical and radiological outcomes were assessed retrospectively. Results Most patients (15) had central glenoid wear A2 as per the Walch classification. There was only one intraoperative complication of a calcar fracture, with no immediate postoperative complications. The average duration of follow-up was 48.8 months. All patients had significantly better range of motion postoperatively and an improvement in Oxford Shoulder Score. A total of 22 patients did not have any pain in the shoulder at the last clinic follow-up, with 100% patient satisfaction following the surgery. Graft was incorporated in all but two patients (89.5%). No patients required revision surgery. Conclusion Our new technique described for glenoid augmentation with humeral head bone graft is an effective technique for addressing glenoid bone defects in reverse shoulder arthroplasty, with good functional outcomes at long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.